MENLO PARK, Calif. - A recent study published in the American Journal of Ophthalmology has shown that the OMNI Surgical System, developed by Sight Sciences Inc. (NASDAQ: NASDAQ:SGHT), is effective in reducing intraocular pressure (IOP) in patients with primary open-angle glaucoma (POAG) over a period of 36 months. The retrospective analysis, which drew data from the American Academy of Ophthalmology’s IRIS Registry, evaluated 230 eyes from 196 patients. According to InvestingPro data, Sight Sciences maintains a strong gross profit margin of 85% and generates annual revenue of nearly $80 million, though the company is currently working toward profitability.
The study, led by Dr. Nathan M. Radcliffe of Mount Sinai School of Medicine, reported that the mean baseline IOP of 22.1 mmHg was significantly reduced to a range of 15.1 to 16.7 mmHg postoperatively. These results were maintained throughout the 36-month follow-up period. Additionally, a notable decrease in the need for IOP-lowering medications was observed, with the mean number of medications dropping from 2.1 at baseline to between 1.1 and 1.6 during the observed period.
Patients with higher baseline IOP levels experienced even greater reductions, and those with lower baseline IOP maintained medication reduction throughout the 36 months. The OMNI Surgical System facilitates a minimally invasive glaucoma surgery (MIGS) procedure that does not require an implant and targets three areas of outflow resistance associated with glaucoma.
Paul Badawi, President and CEO of Sight Sciences, expressed enthusiasm over the study’s findings, emphasizing the potential of the OMNI system to set new standards in MIGS and improve patient care for those affected by glaucoma.
The IRIS Registry, which provided data for the study, is a comprehensive eye disease clinical registry in the United States, boasting over 851 million patient encounters and 80 million unique de-identified patients to date.
This study is part of ongoing efforts by Sight Sciences to deliver innovative and data-driven interventional technologies in eyecare. The company’s portfolio also includes the TearCare System for the treatment of evaporative dry eye disease due to meibomian gland dysfunction.
The findings of this study, based on a press release statement, offer valuable insights for ophthalmologists in the management of POAG, supporting the effectiveness of the OMNI Surgical System in real-world clinical settings. While the company’s stock has faced challenges, declining 45% over the past six months, InvestingPro analysis suggests the stock is currently trading below its Fair Value. InvestingPro subscribers can access 8 additional key insights about SGHT, along with comprehensive financial analysis in the Pro Research Report, which transforms complex Wall Street data into actionable intelligence for smarter investing decisions.
In other recent news, Sight Sciences has secured an additional $5 million in loan funding from its existing credit facility with Hercules Capital (NYSE:HTGC), Inc. and affiliates, bringing the total borrowed amount to $40 million. The loan is part of a senior secured term loan facility that could reach up to $65 million and is set to mature on July 1, 2028. The company’s third-quarter revenue rose 1% year-over-year to $20.2 million, despite a sequential decrease in surgical glaucoma revenue of 8% and a 4% decline in dry eye revenue to $1.5 million. UBS has initiated coverage of Sight Sciences with a Buy rating, forecasting strong sales growth by 2026. The UBS analyst expects the company’s TearCare Dry Eye solution to drive double-digit sales growth and gross margin expansion that exceeds consensus estimates for 2026 and beyond. Sight Sciences remains optimistic about growth in the surgical glaucoma and dry eye segments in 2025, despite current setbacks. The company is contesting the final 2025 Medicare payment rule, which did not grant device-intensive status to OMNI procedures. These are recent developments in the company’s operations and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.